Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram-Negative Peritonitis

    loading  Checking for direct PDF access through Ovid


To determine whether treatment with recombinant human tissue factor pathway inhibitor (TFPI), an inhibitor of the extrinsic coagulation pathway, can improve survival in a clinically relevant model of gram-negative sepsis, rabbits were given an intraperitoneal inoculation of a suspension containing hemoglobin (40 μg/mL), porcine mucin (150 μg/mL), and viable Escherichia coli O18:K1 (1.0 ± 0.5 × 105 cfu/kg). Treatment with gentamicin (5 mg/kg every 12 h for five doses) was instituted 4 h after induction of peritonitis. At the same time point, rabbits were randomized to receive a 24-h infusion of vehicle or one of three different doses of TFPI. Treatment groups, 7-day survival rates, and significance versus control were as follows: control, 1 of 20; TFPILOW DOSE (0.1 mg/kg, then 1 μg/kg/min), 3 of 12 (P = .14); TFPIMID DOSE, (0.5 mg/kg, then 5 μg/kg/min), 7 of 12 (P = .002); TFPIHIGH DOSE (10 mg/kg, then 10 μg/kg/min), 4 of 13 (P = .04). Thus, delayed treatment with TFPI improves survival in septic rabbits.

Related Topics

    loading  Loading Related Articles